TC
ARLZ

TFS Capital’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

TFS Capital’s Portfolio ARLZ Stock Details ARLZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-71,556
Closed -$97K – 594
2017
Q2 		$97K Buy
+71,556
New +$103K 0.04% 552
2017
Q1 		– Sell
-15,031
Closed -$66K – 1017
2016
Q4 		$66K Buy
+15,031
New +$71.4K 0.02% 668
2016
Q2 		– Sell
-250,969
Closed -$891K – 1388
2016
Q1 		$891K Buy
+250,969
New +$1.29M 0.13% 287

Other funds holding ARLZ

PCM
PAR Capital Management Boston, Massachusetts $3.45B AUM 28.5% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
BAS
Brown Advisory Securities Baltimore, Maryland $27.3M AUM 10.67% 1-Year Est. Return

TFS Capital's ARLZ Position: Q3 2017 in Review

TFS Capital sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q3 2017, closing a stake of 71,556 shares — an estimated $97K sold.

TFS Capital first reported a position in ARLZ in Q1 2016 and held it in 3 quarters. The position peaked at $891K in Q1 2016. 59 funds tracked by Wall St. Rank hold ARLZ as of Q3 2017.

  • TFS Capital reported no remaining Aralez Pharmaceuticals Inc. position as of Q3 2017 after selling out during the quarter.
  • TFS Capital sold 71,556 Aralez Pharmaceuticals Inc. shares in Q3 2017, an estimated $97K.
  • TFS Capital first reported a position in Aralez Pharmaceuticals Inc. in Q1 2016 and held it in 3 quarters.
  • TFS Capital's Aralez Pharmaceuticals Inc. position peaked at $891K in Q1 2016.
  • 59 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q3 2017.

Based on TFS Capital's 13F filing for Q3 2017.